You He-Yang, Wu Lei, Yang Hai-Ting, Yang Chen, Ding Xiao-Ling
Department of Neurology, Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230000, China.
Pain Res Manag. 2019 Jan 22;2019:3150306. doi: 10.1155/2019/3150306. eCollection 2019.
Pain is frequent in Parkinson's disease (PD) and Parkinson-plus syndrome. This study aimed to assess the prevalence, characteristics, therapy (especially the effect of dopaminergic therapy), and associated symptoms of pain in Parkinson's disease and multiple system atrophy (MSA) patients.
Seventy-one PD patients, sixty-five MSA patients, and forty age-matched healthy controls were enrolled and evaluated by using the German pain questionnaire and visual analogue scale (VAS). In addition, the influence of pain in PD patients on anxiety, depression, and the quality of life was assessed with the Hospital Anxiety and Depression Scale (HADS) and Parkinson's Disease Questionnaire (PDQ-39).
Compared to that of the healthy controls, the PD and MSA patients had a significantly higher presence of pain ( < 0.01, < 0.01). PD patients had a higher presence of pain than MSA patients (=0.007). No difference in VAS scores was observed between the PD and MSA patients (=0.148). A total of 21 PD patients (42.85%) with pain and 13 MSA patients (43.33%) with pain received treatment. A total of 13 PD patients with pain and 6 MSA patients with pain had an improved pain intensity after using dopaminergic medication. The differences in the disease duration, Hoehn and Yahr stages, and scores on the Unified Parkinson's Disease Rating Scale motor score, HAD-D, HAD-A, and PDQ-39 were significant between the PD patients with and without pain.
PD and MSA patients are prone to pain with insufficient treatment. Pain interventions should be provided as soon as possible to improve the patient's life.
疼痛在帕金森病（PD）和帕金森叠加综合征中很常见。本研究旨在评估帕金森病和多系统萎缩（MSA）患者疼痛的患病率、特征、治疗方法（尤其是多巴胺能治疗的效果）以及相关症状。
纳入71例PD患者、65例MSA患者和40例年龄匹配的健康对照，采用德国疼痛问卷和视觉模拟量表（VAS）进行评估。此外，使用医院焦虑抑郁量表（HADS）和帕金森病问卷（PDQ - 39）评估PD患者疼痛对焦虑、抑郁和生活质量的影响。
与健康对照相比，PD和MSA患者的疼痛发生率显著更高（<0.01，<0.01）。PD患者的疼痛发生率高于MSA患者（=0.007）。PD和MSA患者之间的VAS评分无差异（=0.148）。共有21例疼痛的PD患者（42.85%）和13例疼痛的MSA患者（43.33%）接受了治疗。共有13例疼痛的PD患者和6例疼痛的MSA患者在使用多巴胺能药物后疼痛强度有所改善。有疼痛和无疼痛的PD患者在病程、Hoehn和Yahr分期以及统一帕金森病评定量表运动评分、HAD - D、HAD - A和PDQ - 39评分方面存在显著差异。
PD和MSA患者容易出现疼痛且治疗不足。应尽快提供疼痛干预措施以改善患者生活。
